‘Very Impressive’ Survival With Combo in First-Line Prostate Cancer Study

— Median overall survival with olaparib plus abiraterone reached 68 months in mid-stage trial February 27, 2026 • 3 min read SAN FRANCISCO — The first-line combination of olaparib (Lynparza) plus abiraterone (Zytiga) led to a significant overall survival (OS) advantage for patients with metastatic castration-resistant prostate cancer (mCRPC) harboringContinue Reading

Three deaths reported in Ugandan outbreak

Another outbreak was traced to the consumption and handling of meat Published: February 23, 2026, 12:05 am Researchers have shared details of an outbreak at a funeral in Uganda that killed three young people. Aeromonas bacteria can cause food poisoning with an incubation period of 12 hours to seven days, typically 24Continue Reading